{"id":23612,"date":"2026-06-03T04:30:00","date_gmt":"2026-06-03T08:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-annonce-les-resultats-de-son-assemblee-generale-mixte-du-3-juin-2026\/"},"modified":"2026-06-03T16:42:24","modified_gmt":"2026-06-03T20:42:24","slug":"dbv-technologies-annonce-les-resultats-de-son-assemblee-generale-mixte-du-3-juin-2026","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-annonce-les-resultats-de-son-assemblee-generale-mixte-du-3-juin-2026\/","title":{"rendered":"DBV Technologies annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 3 juin 2026"},"content":{"rendered":"<div class=\"pr-date-globe\">June 03, 2026 16:30 ET<\/div>\n<p align=\"right\">Ch\u00e2tillon, France, le 3 juin 2026 <\/p>\n<p align=\"justify\"><b>DBV Technologies annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 3 juin 2026<\/b><\/p>\n<p align=\"justify\"><b>Toutes les r\u00e9solutions propos\u00e9es \u00e0 l\u2019Assembl\u00e9e G\u00e9n\u00e9rale ont \u00e9t\u00e9 adopt\u00e9es<\/b><\/p>\n<p align=\"justify\">DBV Technologies &lpar;Euronext&nbsp;: DBV \u2013 ISIN&nbsp;: FR0010417345 \u2013 Nasdaq Stock Market&nbsp;: DBVT), &lpar;la \u00ab <b>Soci\u00e9t\u00e9<\/b> \u00bb), soci\u00e9t\u00e9 biopharmaceutique de stade avanc\u00e9, a tenu son Assembl\u00e9e G\u00e9n\u00e9rale Mixte &lpar;l\u2019\u00ab&nbsp;<b>Assembl\u00e9e G\u00e9n\u00e9rale<\/b>&nbsp;\u00bb). L\u2019Assembl\u00e9e G\u00e9n\u00e9rale s\u2019est d\u00e9roul\u00e9e au si\u00e8ge social de la Soci\u00e9t\u00e9, sous la pr\u00e9sidence de Michel de Rosen, Pr\u00e9sident du Conseil d\u2019administration de la Soci\u00e9t\u00e9.<\/p>\n<p align=\"justify\">Toutes les r\u00e9solutions pr\u00e9sent\u00e9es par le Conseil d\u2019administration ont \u00e9t\u00e9 adopt\u00e9es.<\/p>\n<p align=\"justify\">Ces r\u00e9solutions et leurs r\u00e9sultats sont accessibles sur le site internet de la Soci\u00e9t\u00e9&nbsp;: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=77vUbb94jyL0C-i22i9fBRPOBr9KkcBWfC2b60kU4dBqLxmn-KZ9q_h41knuDU04EYJAfm2MkHb5rpVw198v4MXjtii7k3sVxGbK7KC8jDb0vhDg1skB71TmHUGZOVnlNoNQ4gFfKBuSNFKnJkF9UeX6ymUN4RYj0dwZI8qXHWKPRQjSWVw6o0c35JSj-4sUtF_09VULnzcEkAGuiOUI1g==\" rel=\"nofollow\" target=\"_blank\" title=\"Assembl\u00e9e G\u00e9n\u00e9rale Mixte 2026 | DBV Technologies\">Assembl\u00e9e G\u00e9n\u00e9rale Mixte 2026 | DBV Technologies<\/a><\/p>\n<p align=\"left\"><b>\u00c0 propos de DBV&nbsp;Technologies<\/b><br \/>DBV Technologies est une soci\u00e9t\u00e9 biopharmaceutique en phase avanc\u00e9e qui d\u00e9veloppe des options de traitement pour les allergies alimentaires et d\u2019autres conditions immunologiques dont les besoins m\u00e9dicaux ne sont pas satisfaits. DBV Technologies se concentre actuellement sur l\u2019\u00e9tude de l\u2019utilisation de sa plateforme technologique propri\u00e9taire, VIASKIN, pour traiter les allergies alimentaires, qui sont caus\u00e9es par une r\u00e9action immunitaire hypersensible et caract\u00e9ris\u00e9es par une s\u00e9rie de sympt\u00f4mes dont la gravit\u00e9 varie de l\u00e9g\u00e8re \u00e0 l\u2019anaphylaxie mortelle. Des millions de personnes vivent avec des allergies alimentaires, y compris de jeunes enfants. Gr\u00e2ce \u00e0 l\u2019immunoth\u00e9rapie \u00e9picutan\u00e9e &lpar;EPIT\u2122), la plateforme VIASKIN est con\u00e7ue pour introduire des quantit\u00e9s de microgrammes d\u2019un compos\u00e9 biologiquement actif dans le syst\u00e8me immunitaire \u00e0 travers une peau intacte. L\u2019EPIT est une nouvelle classe de traitement non invasif qui cherche \u00e0 modifier l\u2019allergie d\u2019un individu en r\u00e9\u00e9duquant le syst\u00e8me immunitaire pour qu\u2019il devienne d\u00e9sensibilis\u00e9 \u00e0 l\u2019allerg\u00e8ne en tirant parti des propri\u00e9t\u00e9s de tol\u00e9rance immunitaire de la peau. DBV Technologies s\u2019est engag\u00e9e \u00e0 transformer le traitement des personnes souffrant d\u2019allergies alimentaires. Les programmes d\u2019allergie alimentaire de la Soci\u00e9t\u00e9 comprennent des essais cliniques en cours sur VIASKIN Peanut chez les jeunes enfants &lpar;de 1 \u00e0 3 ans) et les enfants &lpar;de 4 \u00e0 7 ans) allergiques \u00e0 l\u2019arachide.<\/p>\n<p align=\"justify\">Le si\u00e8ge social de DBV Technologies se trouve \u00e0 Ch\u00e2tillon, en France, et ses activit\u00e9s nord-am\u00e9ricaines \u00e0 Warren, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris &lpar;DBV, code ISIN : FR0010417345) et les ADS de la Soci\u00e9t\u00e9 &lpar;repr\u00e9sentant chacun cinq actions ordinaires) sont n\u00e9goci\u00e9s sur le Nasdaq Capital Market &lpar;DBVT \u2013 CUSIP : 23306J309).<\/p>\n<p align=\"justify\">Pour plus d\u2019informations, veuillez consulter&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ke7KiPPwqPLXUCqOpT3GPCnzR2lZtRbe97IsD9psRIHPOwg0ayflL09hHMSrzzwrSEvePC6EftKgDkZLeD9H1SmtgfTRGFvVh43f3Wk3EhMZ66-bn0QOfimkcoEZdBMLHe2rN8HAUIbvOSQGPfnUppbBWoR_wtinuwVBeSckyqg_KQttjnB2FLbhfUnkARg7gB_yLhoDl7cbaze1u6P9tMufq9SOoc8X-ixOmRleekJjTtKYhKLjd-zzXfjiJRAVejU7DjkZxBbBQXU1O2TLD_F3WRx_18I_JtuTpM-JemA=\" rel=\"nofollow\" target=\"_blank\" title=\"www.dbvtechnologies.com\">www.dbvtechnologies.com<\/a>&nbsp;et nous contacter sur&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aOrYMiRNA0ejMCuOIyXyX5LumX2TZo9a4FWKuT6e1LCrTnLgyqennEENVhmbq_E-Y84elN4KZJJ1Z-sFx3N0L9oTB-OpjptWeWN8YAF6HslEe0k0syHaJQkTv1Vr8miSYglf_H9QTi-U0BryqnOqoYD5ckT1XEkCzXbqFE8j5Ex-m0x6bwGIeGi7HpgTlECCcg49Tz1JeBvFuhFUM2dTCQQoD4czwye6Z11wKWFs-Zgbtb31qyqynd6CcnSKZ8BK036z3t610AWx9IeThKumzI9MCOZRjVNEzjVEnkRdCOY=\" rel=\"nofollow\" target=\"_blank\" title=\"X &lpar;anciennement Twitter)\">X &lpar;anciennement Twitter)<\/a>&nbsp;et&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uLBWLjoA5IQB5ZmyuqfxYsMcojvNVwXTRnjCe4bl709Y_1IeCaYXm4r-s1_6DznavUqsfY5xqadylJjs7KV8d5u0YNQDtjn6jT154XBiIdb1vsbipUOW-uRUeXMbg8BAZ044BoJz-uuyL4M851FaJ9bWPjo3hME4GU-rsRsixNrad8XOZRttb8pxZEJ6I1xpNGKCXHGIEuAPIB7Ym7yGDYnlQG-ROADSicV9GjhZYl5o0bPGA8NUDHeotWEVSMsFECbt-spoSjfuPUjmqCa6hw==\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\"><b>VIASKIN est une marque d\u00e9pos\u00e9e de DBV Technologies.<\/b><\/p>\n<p align=\"justify\"><b>Contact investisseurs<\/b><br \/>Jonathan Neely<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WKyq3QamOTDL_NDMQCnmNrIW5zHl4_yeuy8tsTUOURwaXLrmw1i4adLk2X0cQw8NPUDejDJIDKQyztAum5Mm0ESHOCFD01s7xSTBjM8-hlhafqy8xPwManUP69MeoSEi1R_lSlJbPU1BmihT2rVQKQ==\" rel=\"nofollow\" target=\"_blank\" title=\"jonathan.neely@dbv-technologies.com\">jonathan.neely@dbv-technologies.com<\/a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p align=\"justify\"><b>Contact m\u00e9dias<\/b><br \/>Brett Whelan<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O30kedaFWJ7NPxFWxdFyazbRR8f73yqEWLjXf5eYag_BK5Mvd6vGur8LPDTuHIjydmnlc0IrrZ2PLpDOjtxtVJiihhUeWHdSFkPqIjLldgwxkxk7ETalXwFWYaZ7xEyo4hUSoZeoS-D950R_lroIVQ==\" rel=\"nofollow\" target=\"_blank\" title=\"brett.whelan@dbv-technologies.com\">brett.whelan@dbv-technologies.com<\/a><\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=NwJhsDN1W43Pf4KqTdcmD20bQMK4Q-Y1h_LqYX9CjYeQVundPtlvNmsPmhJ8DlSeJE2BnF7nORyW4fCli9GiqAellLfcb_WS92jk1BhdCWH4LzoY6crOjco7wdN3Sh81LF_8NMqBwTKnRBxFG3v7V3S6wCLcki5aZhtVY0SKnmA=\" title=\"version PDF\" rel=\"nofollow\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" alt=\"\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/OTBhNDczY2UtOTcyMi00NzU2LTk0OWYtMTRjYTJhODFjMGMxLTEwMTExNTItMjAyNi0wNi0wMy1mcg==\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">            <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[47],"class_list":["post-23612","press_releases","type-press_releases","status-publish","hentry","press_release_type-amf-filing"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/23612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/23612\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=23612"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=23612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}